Recent

% | $
Quotes you view appear here for quick access.

Market Vectors Junior Gold Miners ETF Message Board

jrdelane 2382 posts  |  Last Activity: May 28, 2016 8:07 PM Member since: Dec 5, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • From $0.60 recent high now .35, seems like it, that high was before they won the suit and now there's a sealed settlement. My last buys were $.40, but now it seems apparent there's no big settlement going to be announced, and that faded expectations, now traders are leaving, some profits were harvested.

    It's time to "buy with both fists", as they say. I think the 42.6% retracement from the recent highs of $.61 is a "good enough" margin to take the fluff out of the stock. Patents are intact, court awarded validation, so the coast is clear for the Company to finally execute on it's business plan, and I for one am confident in our fearless leader Keith to take it to the markets and prove the value. All we need is to give the man the time and show faith he deserves after all that has happened.

  • If you pay attention to technical analysis, Tuesday is a very important day for our charts, being the last trading day in May. If we close up over 2.31 the monthly chart puts in a 5th white candle (green on some programs) instead of the currently red candle, down .02, sustaining the uptrend started in January. This week we gained $.06 which is almost nothing except as it relates to giving us a second white (or green) candle on the weekly chart. Further, we have successfully made a bullish cross on MACD for the daily chart, that's a big deal actually.

    The MACD on the weekly chart has been poised to make a bearish MACD cross with how the month of May started, but so far with the intra-month trend reversal, and an up week with flat closes on Weds-Friday, we have only kissed the signal line and not crossed it. If we have an up day on Tuesday, we will avoid this bearish MACD crossover which would avert algos in programmed trading from kicking in with a sell signal.

    Absent news, we just need a slight push on Tuesday to have slammed the efforts of the bears in the month of May, let's do it! I say we finish Tuesday's trade with what we need, at least a few pennies, that's my 2 cents! Show up with your orders near the close on Tuesday if you are still in accumulation mode.

    Sentiment: Strong Buy

  • Reply to

    75 day Restriction - July 18

    by solo_nyc May 17, 2016 2:20 PM
    jrdelane jrdelane May 27, 2016 10:40 AM Flag

    Are you invested, did you buy shares, or are you just investigating and thinking about buying in?

  • jrdelane jrdelane May 27, 2016 1:39 AM Flag

    One thing I said was wrong, I said "we still need to clear the downtrend showing the THREE large full-channel retracements" when in fact there were only TWO large full-channel retracements. And as aptly pointed out, the selling in each of these two related to trial news interpreted by the market as bad news, when in fact the market was wrong the second time. It won't happen again like this.

  • Reply to

    Will shorts lose the battle for the chart?

    by jrdelane May 25, 2016 8:40 PM
    jrdelane jrdelane May 26, 2016 1:13 PM Flag

    "any higher and the monthly chart shows the month of June" meant to say May. Go ATHX, where's the volume?

  • Reply to

    Will shorts lose the battle for the chart?

    by jrdelane May 25, 2016 8:40 PM
    jrdelane jrdelane May 26, 2016 11:25 AM Flag

    Any investors here interested in the evolution of our chart? Right now, the monthly candle is red but if we close at 2.31 we close flat for the month, any higher and the monthly chart shows the month of June as a continuation of the previous four months, with a white candle. We want to break the shorts back, cause them to cover higher, and move out of this two year downtrend of lower highs. I think we close the month higher, not flat, anyone care to chime in, waht do you see?

  • Reply to

    Latest Healios KK Stock price

    by jrdelane May 22, 2016 11:20 PM
    jrdelane jrdelane May 26, 2016 11:09 AM Flag

    Healios KK
    TYO: 4593 - May 26, 3:00 PM GMT+9
    1,900.00 JPY Price decrease 30.00 (1.55%)

  • Reply to

    Not a peep from anyone?

    by biotrader922 May 23, 2016 8:03 PM
    jrdelane jrdelane May 26, 2016 12:36 AM Flag

    The less I have posted the better the stock does, going off posting and taking my work in real estate to the streets has been a double positive.

  • The stakes are high, as shorts are losing their chance to hold the stock down against the bullish fundamentals being embraced of late by holders and institutional investors. The daily chart today made progress as the MACD crossed over the signal line ever so slightly, after a long descent of the MACD below the signal line since March 28th. A bullish MACD crossover is often accompanied by a volume/price move to the upside.

    Other indicators showing as bullish today were ADX, RSI, SloSto, and KST. The weekly chart shows a flattening of the MACD right at the signal line, meaning the bearish crossover is stalling at the last possible moment. A strong couple of days will move us decidedly out of the consolidation triangle pattern mentioned in another thread here today. That is what is at stake, both of these crossovers are at a critical stage to keep our charts bullish, we need follow the next two days.

    The short thesis I'm guessing is built around the last two years of not holding our highs, and the time lag associated in biotech news on advancing catalysts and trials. Shorts prey on lack of news flow in developmental biotech, even where strong fundamentals exist. Our strength now is bolstered by an increasing institutional investment as noted on this board by others.

    It will be important to pay particular attention to the final minutes of each trading day. Timing your buys both in the morning weakness and the late day final minutes will serve to protect your best interests in supporting our stock and getting more well priced shares. Today we were robbed of a penny at final trade. GLTU

    Sentiment: Strong Buy

  • Reply to

    EAM investors added 851,967 shares!

    by unemonl May 25, 2016 1:21 PM
    jrdelane jrdelane May 25, 2016 1:35 PM Flag

    Good information, also, provide a link about the Reuters Buy recommendation if you have one. Thanks.

  • jrdelane jrdelane May 25, 2016 1:34 PM Flag

    Yes, on the monthly chart we still need to clear the downtrend showing the three large full-channel retracements you see. From my downtrend line on my monthly chart, it would appear we need to have a monthly close in the 2.75-2.80 range in order to rise above this historical trend of lower highs in the last 2 years and 5 months, from January of 2014 when the stock made it's highest intraday high of $4.33. The other touch points on the resistance line were 3.43 in April of 2015, and 2.90 in March of this year. The daily and weekly charts are pointing to this trend reversal in progress.

    On another note, about 15 minutes ago, approximately 1:15 Eastern time, there was an order on the buy side for 76,300 shares at 2.29 that was pulled after only a few minutes. I didn't see it reflected on level 2, but notice our daily volume has taken a jump to now 131,000 shares, so maybe it did fill? Now we are seeing a sell order at 2.31 for 45,400 shares. Yesterday there was size at 2.30 on the ask, unfilled. Someone is selling into this rally, let's hope we continue to get volume. Volume precedes price is what they say.

  • jrdelane jrdelane May 25, 2016 9:59 AM Flag

    I noticed this triangle forming on my daily chart, for the last month, agree with Recognia, and in fact the triangle is very tight now and today at 2.29 we are above the descending line, outside and above the triangle, in the continuation part of the pattern. I have been accumulating for the last month, picked up many shares in the 2.17-2.23 range. GLTU

  • The recent collaboration of Universal Cells and Healios will enable Healios to gain the "Universal Donor" status of their iPSC cells they are developing for various indications, and which they also covet in Athersys' MultiStem. Universal donor cells are best described in this article I found:

    Universal Donor Cells Suitable for Any Patient Who Needs Myocardial Repair
    Martha Kerr

    November 20, 2006 (Chicago) — Repairing a damaged myocardium with "universal donor" cells — using stem cells from an unrelated donor, or even an animal — is approaching clinical trials, after successful results of early trials being conducted at McGill University in Montreal, Quebec, Canada.

    The results were presented here during the American Heart Association 2006 Scientific Sessions by investigator Ray C-J. Chiu, MD, professor of surgery and chair emeritus at McGill University. He said the key has been using marrow stromal cells, which are "uniquely immune tolerant."

    Marrow stromal cells, taken from a human male donor, were labeled and injected at multiple sites around an area of infarct in the myocardium of rats with myocardial infarctions.

    The stromal cells were observed not only to survive but to differentiate in the rat myocardium. Some of the cells even began to express cardiomyocyte markers, such as troponin-1c and connexin-43, Dr. Chiu reported.

    Ejection fraction increased from 35.2% to 43.8% ( P

  • jrdelane jrdelane May 24, 2016 11:35 PM Flag

    George, this has been posted there for quite some time, you are new here, we've all seen that. Announcements are not coming on the settlement of the first case in California, which is a sealed settlement with gag order.

  • Reply to

    Going into long weekend

    by xargolf May 24, 2016 11:02 AM
    jrdelane jrdelane May 24, 2016 11:30 PM Flag

    Don't think so, but we are getting close to getting some news on the submission of the J-IND which if they announce that, 5-7% is in the bag! The gains have been slowly made, begrudgingly albeit. If we can continue the trend this week with no back sliding, or have a strong day at least, the MACD bullish cross is threatening to happen and would if we continue up until Friday. That spells good things going into June. The bearish MACD cross on the weekly may yet happen this week, we are touching now, two strong days would cause it to kiss but not cross, very interesting!!

  • Reply to

    Coincidence or Red Flag? - Aspire

    by solo_nyc May 24, 2016 12:57 PM
    jrdelane jrdelane May 24, 2016 3:19 PM Flag

    Solo, you may be right, however there is another Company Athersys who has had an agreement with Aspire and they've not let it hold them back, they have sold them shares as set forth in the agreement. ATHX stock has been rising unlike the situation here.

  • Reply to

    Latest Healios KK Stock price

    by jrdelane May 22, 2016 11:20 PM
    jrdelane jrdelane May 24, 2016 9:51 AM Flag

    Tuesday May 24th Down 4.11 % 1,960.00 JPY Price decrease 84.00 JPY

  • jrdelane jrdelane May 24, 2016 12:33 AM Flag

    Does anyone here know how Athersys has advanced their MultiStem IS treatment regimen to "a scalable off the shelf" product such that there is no danger of patient rejection, much like what Healios aims to do with their iPSC's using Universal Cell's proprietary technology? That is a parallel between Athersys and Universal Cells, Healios is onto this enormous game changing shift that will catapult them to a dominant first to market position in regenerative medicine.

    The reason for my posting all this on the ATHX board is to underscore the brilliance of Healios, our partner. Their success will be a world first, and Athersys is right there, as Hardy said..."and this is a moment." This 'organ bud' technology will be of mind boggling importance to the world's patients, as will our MultiStem for IS, ARDS, and AMI.

    Sentiment: Strong Buy

  • jrdelane jrdelane May 23, 2016 11:59 PM Flag

    “iPSC regenerative medicine is our core business. When iPSC regenerative medicine with less risk of transplant rejection can be developed from iPS cells regardless of HLA type, safety of treatment is improved, and treatments for a variety of diseases can be developed. This technology enhances clinical application of iPS cell technology,” commented Dr. Hardy Kagimoto, President, representative director and CEO of Healios.

    During the option period, Universal Cells will engineer Healios’ clinical-grade iPSCs. The exclusive option is for the treatment of dry/wet AMD, and for use with Healios’ proprietary Organ Bud technology in liver and kidney clinical fields."

  • Explaining perhaps another reason that Healios' stock price has more than doubled since February 12th is their collaboration with AThersys, and two months later with Universal Cells, a private company out of Seattle. Here's the PR:

    "Universal Cells Inc. and Healios K.K. enter Collaborative Research Agreement with Exclusive Option to Produce Universal Donor iPSCs
    April 6, 2016 (Seattle)-Universal Cells Inc. (Seattle WA, USA) and HEALIOS K.K. (“Healios”) (Tokyo, Japan) have entered into a collaborative research and exclusive option agreement to create therapeutic off-the-shelf iPSCs. The partnership will focus on the production of Universal Donor iPSCs by editing the genes required for antigen presentation.

    “Partnering with the world’s leading company in iPSC therapeutics, and the leading nation for accelerated regulatory approval for regenerative medicine products is a significant step towards bringing universal donor cells into the clinic”, commented Dr. Mitchell, CEO of Universal Cells.

    Universal Cells’ technology is based on discoveries by Dr. David Russell, the co-founder and Chief Scientific Officer of Universal Cells, and a world-renowned leader in gene editing. Universal Cells has licensed patents on recombinant adeno-associated viral (rAAV)-mediated gene editing, and HLA engineering.

    With Universal Cells’ proprietary technology, Healios intends to develop next-generation allogeneic iPSCs that are compatible with everyone. Although autologous iPSC manufacturing is feasible, an off-the-shelf cell line has the potential to revolutionize the field of cell therapy by enabling the scalable production of safe, effective, and predictable treatments.

    “iPSC regenerative medicine is our core business. When iPSC regenerative medicine with less risk of transplant rejection can be developed from iPS cells regardless of HLA type, safety of treatment is improved, and treatments for a variety of diseases can be developed. This technology enhances clinical application of

GDXJ
32.89-1.67(-4.83%)May 27 4:00 PMEDT